Arrowhead shareholders elect eight directors, approve executive compensation and share increase

ARROWHEAD PHARMACEUTICALS, INC.

All eight director nominees elected; votes ranged from ~62.8M to ~67.8M in favor.
Advisory vote on executive compensation passed with 62,683,718 for, 7,119,440 against.
Amendment to increase authorized common shares approved: 80,352,213 for, 8,279,373 against.
Ratification of Rose Snyder & Jacobs as auditors passed: 86,613,251 for, 1,296,520 against.
Broker non-votes of ~18.7M were recorded on director election and executive compensation proposals.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

ARROWHEAD PHARMACEUTICALS, INC. shareholders approved Ratification of Rose, Snyder & Jacobs as independent auditors at the 2023-03-16 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-03-16

Exact text from the filing

Ratification of Rose, Snyder & Jacobs as Independent Auditors of the Company 86,613,251 FOR 1,296,520 AGAINST 863,437 ABSTAIN 0 NON VOTES

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

ARROWHEAD PHARMACEUTICALS, INC. shareholders approved Election of eight directors to serve until next annual meeting at the 2023-03-16 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-03-16

Exact text from the filing

Election of Directors NAME FOR AGAINST ABSTAIN NON VOTES Douglass Given 67,160,632 2,517,893 405,240 18,689,443 Michael S. Perry 65,416,779 4,172,284 494,702 18,689,443 Christopher Anzalone 67,517,726 2,257,619 308,420 18,689,443 Marianne De Backer 64,099,823 5,531,033 452,909 18,689,443 Mauro Ferrari 62,760,154 6,726,045 597,566 18,689,443 Adeoye Olukoton 65,203,181 4,295,706 584,878 18,689,443 William Waddill 63,143,044 6,415,395 525,326 18,689,443 Victoria Vakiener 67,756,449 1,797,645 529,671 18,689,443

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

ARROWHEAD PHARMACEUTICALS, INC. shareholders approved Approval of amendment to increase authorized shares of common stock at the 2023-03-16 meeting.

Proposal: charter amendment
Outcome: passed
Meeting: 2023-03-16

Exact text from the filing

Approval of Amendment to Increase Authorized Shares of Common Stock 80,352,213 FOR 8,279,373 AGAINST 141,622 ABSTAIN 0 NON VOTES

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

ARROWHEAD PHARMACEUTICALS, INC. shareholders approved Advisory vote to approve executive compensation at the 2023-03-16 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2023-03-16

Exact text from the filing

Advisory Vote to Approve Executive Compensation 62,683,718 FOR 7,119,440 AGAINST 280,607 ABSTAIN 18,689,443 NON VOTES

View on SEC.gov

Browse all shareholder votes →

ARROWHEAD PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001628280-23-008639

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.